cadherin related family member 4Genealiases: CDH29 · PRO34300
Q-omics provides the consensus-scored CDHR4 profile across patient tissues and cancer cell-line models. CDHR4 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, CDHR4 is differentially expressed in 11, with the highest sampling consensus in LUSC. Additionally, CDHR4 RNA expression shows 12,937 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight KIRC, LUSC, and KIRP as cancer lineages where CDHR4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CDHR4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CDHR4 survival associations across molecular data types. CDHR4 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CDHR4 RNA expression–survival associations across cancer types. High CDHR4 expression shows unfavorable associations in KIRC, UVM, LIHC and LGG, but favorable associations in BRCA and ESCA. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for CDHR4 RNA expression.
This table summarizes CDHR4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for CDHR4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CDHR4 shows lower tumor expression in LUSC and LUAD and higher tumor expression in BRCA, KIRP, KIRC and LIHC. The LUSC box plot shows higher CDHR4 RNA expression in normal versus tumor tissue (log2 FC = −2.361, t-test p < 0.001).
This table shows molecular features associated with CDHR4 in patient tissues and cancer cell lines. In patient samples, CDHR4 shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set. In cancer cell lines, CDHR4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUSC and LARGE_INTESTINE.
